Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Protara Therapeutics (TARA) Consolidated Net Income (2016 - 2026)

Protara Therapeutics' Consolidated Net Income history spans 14 years, with the latest figure at -$18.0 million for Q1 2026.

  • Quarterly Consolidated Net Income fell 42.99% to -$18.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$65.5 million through Mar 2026, down 38.43% year-over-year, with the annual reading at -$59.5 million for FY2025, 29.89% down from the prior year.
  • Consolidated Net Income came in at -$18.0 million for Q1 2026, up from -$18.9 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of -$7.7 million in Q3 2022 to a low of -$38.9 million in Q4 2022.
  • The 5-year median for Consolidated Net Income is -$11.2 million (2024), against an average of -$13.5 million.
  • Year-over-year, Consolidated Net Income tumbled 280.1% in 2022 and then surged 73.71% in 2023.
  • Protara Therapeutics' Consolidated Net Income stood at -$38.9 million in 2022, then soared by 73.71% to -$10.2 million in 2023, then plummeted by 36.98% to -$14.0 million in 2024, then crashed by 35.08% to -$18.9 million in 2025, then increased by 4.97% to -$18.0 million in 2026.
  • Per Business Quant, the three most recent readings for TARA's Consolidated Net Income are -$18.0 million (Q1 2026), -$18.9 million (Q4 2025), and -$13.3 million (Q3 2025).